BTG plc (LON:BTG) had its price target lowered by investment analysts at JPMorgan Chase & Co. from GBX 830 ($10.37) to GBX 800 ($10.00) in a report issued on Wednesday. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 29.24% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank AG reaffirmed a “buy” rating on shares of BTG plc in a research report on Thursday, September 8th. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 900 ($11.24) price objective on shares of BTG plc in a research report on Tuesday. Stifel Nicolaus raised shares of BTG plc to a “buy” rating and upped their price objective for the stock from GBX 640 ($8.00) to GBX 725 ($9.06) in a research report on Thursday, November 3rd. Finally, Royal Bank Of Canada cut shares of BTG plc to a “sector performer” rating and cut their price objective for the stock from GBX 910 ($11.37) to GBX 790 ($9.87) in a research report on Tuesday, November 1st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. BTG plc has an average rating of “Buy” and a consensus price target of GBX 820 ($10.24).

Analyst Recommendations for BTG plc (LON:BTG)

Shares of BTG plc (LON:BTG) opened at 613.50 on Wednesday. The firm’s market cap is GBX 2.35 billion. BTG plc has a 12 month low of GBX 554.97 and a 12 month high of GBX 739.50. The stock’s 50 day moving average is GBX 661.01 and its 200 day moving average is GBX 649.91.

About BTG plc

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.